Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of Nisotirostide in Healthy and Type 2 Diabetes Participants
NCT04641312Phase 1Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2020
- Primary completion
- Dec 2021
- Modality
- Modified Peptides, Native Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of nisotirostide in type 2 diabetes mellitus (T2DM) (4 arms), sponsored by Eli Lilly and Company. Primary endpoint: Number of Participants with One or More Serious Adverse Event(s) Related to Study Drug at Day 42. Started Nov 2020; status: completed.
02
Drugs
nisotirostide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT04641312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04641312.